**Core Concept**
The patient is experiencing a chronic, relapsing form of inflammatory bowel disease (IBD), specifically ulcerative colitis (UC). The use of sulfasalazine, a 5-aminosalicylate (5-ASA) agent, has not provided adequate control of symptoms, and the patient has required steroid therapy to manage flares.

**Why the Correct Answer is Right**
Azathioprine is an immunosuppressive medication that is commonly used as an adjunct therapy in patients with moderate to severe IBD, including UC. It works by inhibiting the proliferation of T and B lymphocytes, thereby reducing inflammation and immune-mediated damage to the gastrointestinal tract. Azathioprine has been shown to reduce the need for steroids and hospitalizations, improve quality of life, and induce and maintain remission in patients with IBD. The mechanism of action involves the inhibition of purine synthesis, which is essential for lymphocyte proliferation.

**Why Each Wrong Option is Incorrect**
**Option A:** Methotrexate is an immunosuppressive agent used in various autoimmune diseases, but it is not the first-line option for IBD. While it can be used in some cases, its use is associated with a higher risk of hepatotoxicity and gastrointestinal side effects.
**Option C:** Cyclosporine is a potent immunosuppressant that can be used in severe cases of IBD, but it is typically reserved for acute, severe flares that are unresponsive to other therapies. Its use is associated with a higher risk of nephrotoxicity and other adverse effects.
**Option D:** Cyclophosphamide is a powerful immunosuppressant that is used in various autoimmune diseases, but it is not commonly used in IBD due to its toxicity profile and the availability of more targeted therapies.

**Clinical Pearl / High-Yield Fact**
When considering the use of immunosuppressive agents in IBD, it is essential to assess the patient's risk of adverse effects and the potential benefits of therapy. Azathioprine and other thiopurines are often used as a first-line option due to their relatively favorable safety profile and efficacy in inducing and maintaining remission.

**✓ Correct Answer: B. Azathioprine**